Pfizer EBITDA 2010-2022 | PFE

Pfizer annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Pfizer EBITDA for the quarter ending September 30, 2022 was $10.126B, a 35.23% increase year-over-year.
  • Pfizer EBITDA for the twelve months ending September 30, 2022 was $38.434B, a 73.84% increase year-over-year.
  • Pfizer 2021 annual EBITDA was $24.624B, a 90.43% increase from 2020.
  • Pfizer 2020 annual EBITDA was $12.931B, a 3.74% increase from 2019.
  • Pfizer 2019 annual EBITDA was $12.465B, a 5.44% increase from 2018.
Pfizer Annual EBITDA
(Millions of US $)
2021 $24,624
2020 $12,931
2019 $12,465
2018 $11,822
2017 $19,991
2016 $17,902
2015 $16,981
2014 $18,786
2013 $21,594
2012 $22,919
2011 $22,993
2010 $21,811
2009 $15,716
Pfizer Quarterly EBITDA
(Millions of US $)
2022-09-30 $10,126
2022-06-30 $13,394
2022-03-31 $10,588
2021-12-31 $4,326
2021-09-30 $7,488
2021-06-30 $6,914
2021-03-31 $5,896
2020-12-31 $1,811
2020-09-30 $3,656
2020-06-30 $3,271
2020-03-31 $4,193
2019-12-31 $-3,799
2019-09-30 $4,511
2019-06-30 $5,794
2019-03-31 $5,959
2018-12-31 $-4,610
2018-09-30 $5,378
2018-06-30 $5,538
2018-03-31 $5,516
2017-12-31 $3,881
2017-09-30 $5,230
2017-06-30 $5,315
2017-03-31 $5,565
2016-12-31 $3,305
2016-09-30 $4,417
2016-06-30 $4,864
2016-03-31 $5,316
2015-12-31 $3,258
2015-09-30 $4,630
2015-06-30 $4,796
2015-03-31 $4,297
2014-12-31 $3,478
2014-09-30 $5,008
2014-06-30 $5,374
2014-03-31 $4,926
2013-12-31 $4,532
2013-09-30 $5,505
2013-06-30 $5,913
2013-03-31 $5,644
2012-12-31 $4,667
2012-09-30 $5,399
2012-06-30 $6,539
2012-03-31 $6,314
2011-12-31 $4,371
2011-09-30 $6,303
2011-06-30 $6,270
2011-03-31 $6,049
2010-12-31 $3,793
2010-09-30 $5,992
2010-06-30 $6,414
2010-03-31 $5,612
2009-12-31 $1,735
2009-09-30 $5,100
2009-06-30 $4,127
2009-03-31 $4,754
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $285.774B $81.288B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $467.679B 18.00
Eli Lilly (LLY) United States $356.089B 44.94
AbbVie (ABBV) United States $289.429B 12.00
Novo Nordisk (NVO) Denmark $287.171B 37.66
Merck (MRK) United States $278.995B 14.37
Novartis AG (NVS) Switzerland $199.112B 15.00